Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

0545446 - ÚI 2022 US eng J - Článek v odborném periodiku
Novák, P. - Schmidt, R. - Kontseková, E. - Žilka, N. - Kováčech, B. - Škrabana, R. - Vince-Kazmerová, Z. - Katina, Stanislav - Fialová, L. - Prčina, M. - Parrak, V. - Dal-Bianco, P. - Brunner, M. - Staffen, W. - Rainer, M. - Ondruš, M. - Ropele, S. - Smíšek, M. - Sivak, R. - Winblad, B. - Novák, M.
Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial.
Lancet Neurology. Roč. 16, č. 2 (2017), s. 123-134. ISSN 1474-4422. E-ISSN 1474-4465
Klíčová slova: paired helical filament * neurofibrillary degeneration * structural determinants * protein-tau * dementia * inhibitor * pathology * consensus * model * core
Impakt faktor: 27.144, rok: 2017

Background Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of Alzheimer's disease. We have developed an active vaccine, AADvac1, against pathological tau proteins and assessed it in a phase 1 trial.
Trvalý link: http://hdl.handle.net/11104/0322131